| Ytd | 57.46% | |
| 1y | 153.36% |
| Open | 121.58 | Prev Close | 120.46 | Low | 119.99 | High | 125.50 | Mkt Cap | 7.58B |
| Vol | 86.72K | Avg Vol | 996.92K | EPS | -13.60 | P/E | N/A | Forward P/E | -1376.69 |
| Beta | 0.51 | Short Ratio | 9.04 | Inst. Own | 114.42% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-05 | 50-d Avg | 101.86 | 200-d Avg | 87.81 | 1yr Est | 145.36 |
MIRM News
Mirum Pharmaceuticals (MIRM) saw its shares surge in the last session with trading volume being high
After a sweeping semi-annual rebalance, the biotech index underlying the ALPS Medical Breakthroughs
Citizens analyst Jonathan Wolleben maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Market Ou
- Cohort 1 results presented at ENDO 2026 demonstrate meaningful reductions in total heterotopic oss
Morgan Stanley analyst Michael Ulz maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Overweigh
The late-breaking rapid-fire presentation will include results from Cohort 1 of the placebo-controll
Citigroup analyst Yigal Nochomovitz initiates coverage on Mirum Pharmaceuticals (NASDAQ:MIRM) wit
Wall Street analysts changed ratings on top names. Check our analyst ratings page for full updates.
Top Wall Street analysts upgraded STUB, PGNY, AMT, and BAP stocks and raised their price targets. Se
Wall Street analysts changed outlook on top names. See analyst ratings page for all changes. Analyst
Wolfe Research analyst Kalpit Patel initiates coverage on Mirum Pharmaceuticals (NASDAQ:MIRM) wit
Miram Pharmaceuticals to offer, subject to market conditions and other factors, $600.0 million aggre
TD Cowen analyst Joseph Thome maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and raises
RBC Capital analyst Lisa Walter maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Outperform a
Evercore ISI Group analyst Gavin Clark-Gartner maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with
Baird analyst Brian Skorney maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Outperform and r
Mirum Pharmaceuticals (NASDAQ:MIRM) reported quarterly losses of $(0.50) per share which missed the
Mirum Pharmaceuticals (NASDAQ:MIRM) raises FY2026 sales outlook from $630.000 million-$650.000 milli
Morgan Stanley analyst Michael Ulz maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Overweigh
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Mirum Pharmaceuticals (NASDAQ:MI
Mirum stock rises after Phase 2b VISTAS data for volixibat; AZURE-1 results and technical levels hig
-Â Statistically significant and clinically meaningful 2.72 point reduction from baseline and 1.64 po
Stifel analyst James Condulis maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and raises
Baird analyst Brian Skorney maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Outperform and r
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Mirum Pharmaceuticals (NASDAQ:MI
-Primary endpoint (virologic response and ALT normalization) achieved in both dose arms at Week 24-F
Citizens analyst Jonathan Wolleben reiterates Mirum Pharmaceuticals (NASDAQ:MIRM) with a Market O
TD Cowen analyst Joseph Thome maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and raises
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Mirum Pharmaceuticals (NASDAQ:M
- Phase 3 AZURE-1 enrollment complete- Phase 3 AZURE-4 screening complete- Topline AZURE-1 and AZURE
Evercore ISI Group analyst Gavin Clark-Gartner maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with
Leerink Partners analyst Mani Foroohar maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Outpe
TD Cowen analyst Joseph Thome maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and raises
RBC Capital analyst Joe Kim maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Outperform and l
Citizens analyst Jonathan Wolleben maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Market Ou
Stifel analyst Dae Gon Ha maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and raises the
Mirum Pharmaceuticals (NASDAQ:MIRM) sees FY2026 sales of $630.000 million-$650.000 million vs $638.3
Mirum Pharmaceuticals (NASDAQ:MIRM) reported quarterly sales of $148.932 million which beat the anal
RBC Capital analyst Joe Kim initiates coverage on Mirum Pharmaceuticals (NASDAQ:MIRM) with a Outp
- Tablet authorization builds upon established use of LIVMARLI oral solution in CanadaMirum Pharmace
Morgan Stanley analyst Michael Ulz maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Overweigh
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Mirum Pharmaceuticals (NASDAQ:MI
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Mirum Pharmaceuticals (NASDAQ:M
Enthorin Therapeutics, LLC, a biotechnology company focused on circuit-modulating treatments for neu